BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 25761977)

  • 1. Efficacy and tolerability of saxagliptin compared with glimepiride in elderly patients with type 2 diabetes: a randomized, controlled study (GENERATION).
    Schernthaner G; Durán-Garcia S; Hanefeld M; Langslet G; Niskanen L; Östgren CJ; Malvolti E; Hardy E
    Diabetes Obes Metab; 2015 Jul; 17(7):630-8. PubMed ID: 25761977
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative effect of saxagliptin and glimepiride with a composite endpoint of adequate glycaemic control without hypoglycaemia and without weight gain in patients uncontrolled with metformin therapy: Results from the SPECIFY study, a 48-week, multi-centre, randomized, controlled trial.
    Gu T; Ma J; Zhang Q; Zhu L; Zhang H; Xu L; Cheng J; Shi B; Li D; Shao J; Sun Z; Zhong S; Bi Y; Zhu D
    Diabetes Obes Metab; 2019 Apr; 21(4):939-948. PubMed ID: 30520221
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of Glimepiride versus Saxagliptin on β-Cell Function and Hypoglycemia: A Post Hoc Analysis in Older Patients with Type 2 Diabetes Inadequately Controlled with Metformin.
    Perl S; Cook W; Wei C; Ohman P; Hirshberg B
    Clin Ther; 2016 Dec; 38(12):2578-2588. PubMed ID: 27823868
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized controlled trial of the efficacy and safety of saxagliptin as add-on therapy in patients with type 2 diabetes and inadequate glycaemic control on metformin plus a sulphonylurea.
    Moses RG; Kalra S; Brook D; Sockler J; Monyak J; Visvanathan J; Montanaro M; Fisher SA
    Diabetes Obes Metab; 2014 May; 16(5):443-50. PubMed ID: 24205943
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial.
    Jadzinsky M; Pfützner A; Paz-Pacheco E; Xu Z; Allen E; Chen R;
    Diabetes Obes Metab; 2009 Jun; 11(6):611-22. PubMed ID: 19515181
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of dapagliflozin or dapagliflozin plus saxagliptin versus glimepiride as add-on to metformin in patients with type 2 diabetes.
    Müller-Wieland D; Kellerer M; Cypryk K; Skripova D; Rohwedder K; Johnsson E; Garcia-Sanchez R; Kurlyandskaya R; Sjöström CD; Jacob S; Seufert J; Dronamraju N; Csomós K
    Diabetes Obes Metab; 2018 Nov; 20(11):2598-2607. PubMed ID: 29947099
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of vildagliptin versus saxagliptin on daily acute glucose fluctuations in Chinese patients with T2DM inadequately controlled with a combination of metformin and sulfonylurea.
    Xiaoyan C; Jing W; Xiaochun H; Yuyu T; Shunyou D; Yingyu F
    Curr Med Res Opin; 2016 Jun; 32(6):1131-6. PubMed ID: 26950829
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term 4-year safety of saxagliptin in drug-naive and metformin-treated patients with Type 2 diabetes.
    Rosenstock J; Gross JL; Aguilar-Salinas C; Hissa M; Berglind N; Ravichandran S; Fleming D
    Diabet Med; 2013 Dec; 30(12):1472-6. PubMed ID: 23802840
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dapagliflozin versus saxagliptin as add-on therapy in patients with type 2 diabetes inadequately controlled with metformin.
    Rosenstock J; Mathieu C; Chen H; Garcia-Sanchez R; Saraiva GL
    Arch Endocrinol Metab; 2018 Aug; 62(4):424-430. PubMed ID: 30304106
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of teneligliptin added to glimepiride in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled study with an open-label, long-term extension.
    Kadowaki T; Kondo K
    Diabetes Obes Metab; 2014 May; 16(5):418-25. PubMed ID: 24205974
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus.
    Scheen AJ; Charpentier G; Ostgren CJ; Hellqvist A; Gause-Nilsson I
    Diabetes Metab Res Rev; 2010 Oct; 26(7):540-9. PubMed ID: 20824678
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of vildagliptin in patients with type 2 diabetes mellitus inadequately controlled with dual combination of metformin and sulphonylurea.
    Lukashevich V; Del Prato S; Araga M; Kothny W
    Diabetes Obes Metab; 2014 May; 16(5):403-9. PubMed ID: 24199686
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naive patients with type 2 diabetes.
    Rosenstock J; Sankoh S; List JF
    Diabetes Obes Metab; 2008 May; 10(5):376-86. PubMed ID: 18355324
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of gemigliptin, a dipeptidyl peptidase-4 inhibitor, in patients with type 2 diabetes mellitus inadequately controlled with combination treatment of metformin and sulphonylurea: a 24-week, multicentre, randomized, double-blind, placebo-controlled study (TROICA study).
    Ahn CH; Han KA; Yu JM; Nam JY; Ahn KJ; Oh TK; Lee HW; Lee DH; Kim J; Chung CH; Park TS; Kim BJ; Park SW; Park HK; Lee KJ; Kim SW; Park JH; Ko KP; Kim CH; Lee H; Jang HC; Park KS
    Diabetes Obes Metab; 2017 May; 19(5):635-643. PubMed ID: 28026912
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of saxagliptin combination therapy in US patients with type 2 diabetes.
    Karyekar C; Donovan M; Allen E; Fleming D; Ravichandran S; Chen R
    Postgrad Med; 2011 Jul; 123(4):63-70. PubMed ID: 21680990
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Saxagliptin is non-inferior to glipizide in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: a 52-week randomised controlled trial.
    Göke B; Gallwitz B; Eriksson J; Hellqvist A; Gause-Nilsson I;
    Int J Clin Pract; 2010 Nov; 64(12):1619-31. PubMed ID: 20846286
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and efficacy of saxagliptin added to thiazolidinedione over 76 weeks in patients with type 2 diabetes mellitus.
    Hollander PL; Li J; Frederich R; Allen E; Chen R;
    Diab Vasc Dis Res; 2011 Apr; 8(2):125-35. PubMed ID: 21562064
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.
    Hermansen K; Kipnes M; Luo E; Fanurik D; Khatami H; Stein P;
    Diabetes Obes Metab; 2007 Sep; 9(5):733-45. PubMed ID: 17593236
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Saxagliptin add-on therapy to insulin with or without metformin for type 2 diabetes mellitus: 52-week safety and efficacy.
    Barnett AH; Charbonnel B; Li J; Donovan M; Fleming D; Iqbal N
    Clin Drug Investig; 2013 Oct; 33(10):707-17. PubMed ID: 23949898
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized, Double-Blind, Phase 3 Trial of Triple Therapy With Dapagliflozin Add-on to Saxagliptin Plus Metformin in Type 2 Diabetes.
    Mathieu C; Ranetti AE; Li D; Ekholm E; Cook W; Hirshberg B; Chen H; Hansen L; Iqbal N
    Diabetes Care; 2015 Nov; 38(11):2009-17. PubMed ID: 26246458
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.